# US 2014/0156198 A1 · Determining Coronary Artery Disease Risk

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0156198 A1
- Document ID: US20140156198A1
- Status: Published application
- Kind: A1
- Application number: 14/157,196
- Filed: 2014-01-16
- Published: 2014-06-05
- Earliest claimed: 2009-06-15
- Assignees: Cardiodx, Inc.
- Applicants: Cardiodx, Inc.
- Inventors: Steven Rosenberg; Michael R. Elashoff; Philip Beineke; James A. Wingrove; Whittemore G. Tingley; Susan E. Daniels
- Web page: https://patentgrep.com/patent/US20140156198A1

## CPC

- G16H 50/30: for calculating health indices; for individual health risk assessment
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/20: Supervised data analysis
- G16B 40/30: Unsupervised data analysis
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q 2600/16: Primer sets for multiplex assays
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Markers and methods useful for assessing coronary artery disease in a subject are provided, along with kits for measuring their expression. Also provided are predictive models, based on the markers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.

## Claims

### Claim 1

A computer-implemented method for scoring a sample obtained from a subject, comprising:
obtaining a dataset obtained from the sample, wherein the dataset comprises data representing age and gender and data representing a quantitative expression level value for each of the markers: S100A12, CLEC4E, S100A8, CASP5, IL18RAP, TNFAIP6, AQP9, NCF4, CD3D, TMC8, CD79B, SPIB, HNRPF, TFCP2, RPL28, AF161365, AF289562, SLAMF7, KLRC4, IL8RB, TNFRSF10C, KCNE3, and TLR4; and
applying an interpretation function to the dataset to mathematically combine, by a computer processor, the data representing the quantitative expression level value for each marker to predict the presence or absence of coronary artery disease (CAD) in the subject, wherein the interpretation function is: Score=INTERCEPT−0.755*(Nup−Ndown)−0.406*(NKup−Tcell)−0.308*SEX*(SCA1−Norms)−0.137*(Bcell−Tcell)−0.548*(1−SEX)*(SCA1−Neut)−0.482*SEX*(TSPAN)−0.246*(AF2−Norm2), wherein Norm1=RPL28, wherein Norm2=(0.5*HNRPF+0.5*TFCP2), wherein NKup=(0.5*SLAMF7+0.5*KLRC4), wherein Tcell=(0.5*CD3D+0.5*TMC8), wherein Bcell=(⅔*CD79B+⅓*SPIB), wherein Neut=(0.5*AQP9+0.5*NCF4), wherein Nup=(⅓*CASP5+⅓*IL18RAP+⅓*TNFAIP6), wherein Ndown=(0.25*IL8RB+0.25*TNFRSF10C+0.25*TLR4+0.25*KCNE3), wherein SCA1=(⅓*S100A12+⅓*CLEC4E+⅓*S100A8), wherein AF2=AF289562, wherein TSPAN=1 if (AF161365-Norm2>6.27 or AF161365=NoCall), 0 otherwise, wherein SEX=1 for Males, 0 for Females, and wherein for males INTERCEPT=2.672+0.0449*Age or for females INTERCEPT=1.821+0.123*(Age-60), if negative set to 0, thereby scoring the sample obtained from the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising applying a second interpretation function to the score from the first interpretation function to transform, by a computer processor, the score from the first interpretation function into a Final Score, wherein the second interpretation function is: Final Score=Score*40/4.52, wherein if the score from the first interpretation function is less than −2.95 then it is set to −2.95, wherein if the score from the first interpretation function is greater than 1.57 then it is set to 1.57, wherein the Score=2.95 plus the score from the first interpretation function, wherein the Final Score is rounded up to the nearest integer, wherein if the Final Score is greater than 40 it is set to 40, and wherein if the Final Score is less than 1 it is set to 1.

### Claim 3 (depends on 1)

The method of claim 1, wherein obtaining the dataset obtained from the sample comprises obtaining the sample and processing the sample to experimentally determine the dataset.

### Claim 4 (depends on 1)

The method of claim 1, wherein obtaining the dataset obtained from the sample comprises receiving the dataset from a third party that has processed the sample to experimentally determine the dataset.

### Claim 5 (depends on 1)

The method of claim 1, further comprising classifying the sample according to the score.

### Claim 6 (depends on 1)

The method of claim 1, further comprising rating CAD risk using the score.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample comprises RNA extracted from peripheral blood cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the data representing quantitative expression level values are hybridization data.

### Claim 9 (depends on 1)

The method of claim 1, wherein the data representing quantitative expression level values are polymerase chain reaction data.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dataset is obtained stored on a storage memory.

### Claim 11 (depends on 1)

The method of claim 1, wherein the CAD is obstructive CAD.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject has stable chest pain, the subject has typical angina or atypical angina or an anginal equivalent, the subject has no previous diagnosis of myocardial infarction (MI), the subject has not had a revascularization procedure, the subject does not have diabetes, the subject does not have a systemic autoimmune or infectious condition, and/or the subject is not currently taking a steroid, an immunosuppressive agent, or a chemotherapeutic agent.

### Claim 13

A system for scoring a sample obtained from a subject, the system comprising:
a storage memory for storing a dataset obtained from a sample obtained from the subject, wherein the dataset comprises data representing age and gender and data representing a quantitative expression level value for each of the markers: S100A12, CLEC4E, S100A8, CASP5, IL18RAP, TNFAIP6, AQP9, NCF4, CD3D, TMC8, CD79B, SPIB, HNRPF, TFCP2, RPL28, AF161365, AF289562, SLAMF7, KLRC4, IL8RB, TNFRSF10C, KCNE3, and TLR4; and
a processor communicatively coupled to the storage memory for applying an interpretation function to the dataset to mathematically combine the data representing the quantitative expression level value for each marker to predict the presence or absence of coronary artery disease (CAD) in the subject, wherein the interpretation function is: Score=INTERCEPT−0.755*(Nup−Ndown)−0.406*(NKup−Tcell)−0.308*SEX*(SCA1−Norm1)−0.137*(Bcell−Tcell)−0.548*(1−SEX)*(SCA1−Neut)−0.482*SEX*(TSPAN)−0.246*(AF2−Norm2), wherein Norm1=RPL28, wherein Norm2=(0.5*HNRPF+0.5*TFCP2), wherein NKup=(0.5*SLAMF7+0.5*KLRC4), wherein Tcell=(0.5*CD3D+0.5*TMC8), wherein Bcell=(⅔*CD79B+⅓*SPIB), wherein Neut=(0.5*AQP9+0.5*NCF4), wherein Nup=(⅓*CASP5+⅓*IL18RAP+⅓*TNFAIP6), wherien Ndown=(0.25*IL8RB+0.25*TNFRSF10C+0.25*TLR4+0.25*KCNE3), wherein SCA1=(⅓*S100A12+⅓*CLEC4E+⅓*S100A8), wherein AF2=AF289562, wherein TSPAN=1 if (AF161365-Norm2>6.27 or AF161365=NoCall), 0 otherwise, wherein SEX=1 for Males, 0 for Females, and wherein for males INTERCEPT=2.672+0.0449*Age or for females INTERCEPT=1.821+0.123*(Age-60), if negative set to 0, thereby scoring the sample obtained from the subject.

### Claim 14 (depends on 13)

The system of claim 13, further comprising a processor for applying a second interpretation function to the score from the first interpretation function to transform the score from the first interpretation function into a Final Score, wherein the second interpretation function is: Final Score=Score*40/4.52, wherein if the score from the first interpretation function is less than −2.95 then it is set to −2.95, wherein if the score from the first interpretation function is greater than 1.57 then it is set to 1.57, wherein the Score=2.95 plus the score from the first interpretation function, wherein the Final Score is rounded up to the nearest integer, wherein if the Final Score is greater than 40 it is set to 40, and wherein if the Final Score is less than 1 it is set to 1.

### Claim 15 (depends on 13)

The system of claim 13, wherein obtaining the dataset obtained from the sample comprises obtaining the sample and processing the sample to experimentally determine the dataset.

### Claim 16 (depends on 13)

The system of claim 13, wherein obtaining the dataset obtained from the sample comprises receiving the dataset from a third party that has processed the sample to experimentally determine the dataset.

### Claim 17 (depends on 13)

The system of claim 13, wherein the processor is further communicatively coupled to the storage memory for classifying the sample according to the score.

### Claim 18 (depends on 13)

The system of claim 13, wherein the processor is further communicatively coupled to the storage memory for rating CAD risk using the score.

### Claim 19 (depends on 13)

The system of claim 13, wherein the sample comprises RNA extracted from peripheral blood cells.

### Claim 20 (depends on 13)

The system of claim 13, wherein the data representing quantitative expression level values are hybridization data.

### Claim 21 (depends on 13)

The system of claim 13, wherein the data representing quantitative expression level values are polymerase chain reaction data.

### Claim 22 (depends on 13)

The system of claim 13, wherein the CAD is obstructive CAD.

### Claim 23 (depends on 13)

The system of claim 13, wherein the subject has stable chest pain, the subject has typical angina or atypical angina or an anginal equivalent, the subject has no previous diagnosis of myocardial infarction (MI), the subject has not had a revascularization procedure, the subject does not have diabetes, the subject does not have a chronic autoimmune condition or a chronic infectious condition, and/or the subject is not currently taking a steroid, an immunosuppressive agent, or a chemotherapeutic agent.

### Claim 24

A computer-readable storage medium storing computer-executable program code for scoring a sample obtained from a subject, the medium comprising:
a dataset obtained from the sample, wherein the dataset comprises data representing age and gender and data representing a quantitative expression level value for each of the markers: S100A12, CLEC4E, S100A8, CASP5, IL18RAP, TNFAIP6, AQP9, NCF4, CD3D, TMC8, CD79B, SPIB, HNRPF, TFCP2, RPL28, AF161365, AF289562, SLAMF7, KLRC4, IL8RB, TNFRSF10C, KCNE3, and TLR4; and
computer-executable program code for applying an interpretation function to the dataset to mathematically combine the data representing the quantitative expression level value for each marker to predict the presence or absence of coronary artery disease (CAD) in the subject, wherein the interpretation function is: Score=INTERCEPT−0.755*(Nup−Ndown)−0.406*(NKup−Tcell)−0.308*SEX*(SCA1−Norm1)−0.137*(Bcell−Teen)−0.548*(1−SEX)*(SCA1−Neut)−0.482*SEX*(TSPAN)−0.246*(AF2−Norm2), wherein Norm1=RPL28, wherein Norm2=(0.5*HNRPF+0.5*TFCP2), wherein NKup=(0.5*SLAMF7+0.5*KLRC4), wherein Tcell=(0.5*CD3D+0.5*TMC8), wherein Bcell=(⅔*CD79B+⅓*SPIB), wherein Neut=(0.5*AQP9+0.5*NCF4), wherein Nup=(⅓*CASP5+⅓*IL18RAP+⅓*TNFAIP6), wherein Ndown=(0.25*IL8RB+0.25*TNFRSF10C+0.25*TLR4+0.25*KCNE3), wherein SCA1=(⅓*S100A12+⅓*CLEC4E+⅓*S100A8), wherein AF2=AF289562, wherein TSPAN=1 if (AF161365-Norm2>6.27 or AF161365=NoCall), 0 otherwise, wherein SEX=1 for Males, 0 for Females, and wherein for males INTERCEPT=2.672+0.0449*Age or for females INTERCEPT=1.821+0.123*(Age-60), if negative set to 0, thereby scoring the sample obtained from the subject.
